In a nutshell This review aims to analyze the trials that led to acalabrutinib (Calquence) gaining regulatory approval in the European Union for the treatment of chronic lymphocytic leukemia (CLL). Some background Acalabrutrinib is a targeted therapy mainly used for the treatment of non-Hodgkin lymphoma. It...
Read MoreType of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor
Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting
In a nutshell This study aimed to investigate whether venetoclax (Venclexta) is effective and well tolerated in patients with chronic lymphocytic leukemia (CLL) in a real-world setting. This study concluded that venetoclax is safe and effective in the real-world setting in these patients. Some background...
Read MoreEvaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL). This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...
Read MoreLooking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.
In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...
Read MoreBlood Cancer Awareness Month: CLL
CLL or Chronic Lymphocytic Leukemia results from a mutation in B lymphocytes, a type of white blood cell that develops in the bone marrow. B-cells produce antibodies, an important part of the immune system. CLL can be slow growing, with small slow changes in the blood counts over years or fast growing, where cancerous B-lymphocytes crowd out the bone...
Read MoreComparing front-line treatments for older patients with chronic lymphocytic leukemia
In a nutshell This study aimed to compare the safety and effectiveness of bendamustine–rituximab (BR) and chlorambucil–rituximab (Chl-R) as a front-line treatment in older patients with chronic lymphocytic leukemia (CLL). This study concluded that both treatments are good options for these...
Read MoreThe impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib
In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...
Read MoreZanubrutinib treatment for relapsed or unresponsive chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients. Some background Bruton...
Read MoreManaging patients with leukemia during the COVID-19 pandemic
In a nutshell The report recommends several treatment modifications for patients with leukemia during the high-risk period of the COVID-19 pandemic. The main recommendations are to reduce clinic visits, use less intensive chemotherapy, and care through telemedicine for effective treatment. Some background Managing patients with leukemia during...
Read MoreLong-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the outcomes of anti-CD19 chimeric antigen receptor T cells in patients with relapsed or refractory (unresponsive) chronic lymphocytic leukemia. This study concluded that high-dose treatment may be more effective in these patients in the long term. Some background Chimeric antigen...
Read MoreIbrutinib for first-line and relapsed/refractory chronic lymphocytic leukemia: long-term outcomes
In a nutshell This study aimed to investigate the long-term safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study concluded that ibrutinib was safe and effective in the long-term in this group. Some background Ibrutinib (Imbruvica) is a...
Read MoreCombining obinutuzumab and chlorambucil in unfit patients with chronic lymphocytic leukemia
In a nutshell The study evaluated the effectiveness of combining obinutuzumab (Gazyva) and chlorambucil (Leukeran) (O-Clb) to treat physically unfit patients with chronic lymphocytic leukemia (CLL). The authors found that O-Clb is a safe and effective initial treatment for unfit patients with low-risk CLL in a real-world setting. Some background...
Read More